Sepsis and treatment-induced immunosuppression in the patient with cancer

Critical Care Nursing Clinics of North America

Volumn 15, Issue 1, 2003, Pages 109-118

  Reigle, Beverly S ^a   Dienger, M Joyce ^a  

^a UNIVERSITY OF CINCINNATI   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

ACICLOVIR; AMINOGLYCOSIDE ANTIBIOTIC AGENT; AMOXICILLIN PLUS CLAVULANIC ACID; AMPHOTERICIN B; ANTIBIOTIC AGENT; ANTIINFECTIVE AGENT; ANTINEOPLASTIC AGENT; ASPARAGINASE; CARBAPENEM; CEFEPIME; CEFIXIME; CEFTAZIDIME; CIPROFLOXACIN; CLADRIBINE; CORTICOSTEROID; COTRIMOXAZOLE; CYCLOPHOSPHAMIDE; CYCLOSPORIN; GLUCOCORTICOID; GRANULOCYTE COLONY STIMULATING FACTOR; GRANULOCYTE MACROPHAGE COLONY STIMULATING FACTOR; MELPHALAN; MERCAPTOPURINE; METHOTREXATE; PENICILLIN G; QUINOLINE DERIVED ANTIINFECTIVE AGENT; VANCOMYCIN; VINCRISTINE;

ANTIBIOTIC RESISTANCE; BACTERIAL INFECTION; CANCER; CANCER RADIOTHERAPY; CELL COUNT; CELLULAR IMMUNITY; DRUG MEGADOSE; GRANULOCYTOPENIA; HUMAN; HUMORAL IMMUNITY; IMMUNE DEFICIENCY; IMMUNOSUPPRESSIVE TREATMENT; INFECTION; LYMPHOCYTOPENIA; MUCOSA INFLAMMATION; NEUTROPENIA; NEUTROPHIL; REVIEW; SEPSIS; ANTIBODY PRODUCTION; DRUG EFFECT; IMMUNOLOGY; NEOPLASM; RADIATION EXPOSURE; RADIOTHERAPY;

ANTIBODY FORMATION; ANTINEOPLASTIC AGENTS; HUMANS; IMMUNITY, CELLULAR; IMMUNOCOMPROMISED HOST; NEOPLASMS; NEUTROPENIA; RADIOTHERAPY; SEPSIS;

EID: 0037365693     PISSN: 08995885     EISSN: None     Source Type: Journal    
DOI: 10.1016/S0899-5885(02)00038-2     Document Type: Review

References (37)

1. Balk R.A. Severe sepsis and septic shock: definitions, epidemiology, and clinical manifestations. Crit Care Clin. 16:(2):2000;179-192
2. Freifeld A.G., Walsh T.J., Pizzo P.A. Infections in the cancer patient. DeVita V.T. Jr., Hellman S., Rosenberg S. Cancer: principles and practice of oncology. 5th edition:1997;2659-2704 Lippincott-Raven, Philadelphia
3. Engervall P., Bjorkholm M. Infections in neutropenic patients. I. Aetiology. Med Oncol. 12:(4):1995;251-256
4. Safdar A., Armstrong D. Infectious morbidity in critically ill patients with cancer. Crit Care Clin. 17:(3):2001;531-570
5. Wiernik P.H. Neutrophil function in infection. Mediguide to Infectious Diseases. 9:(1):1989;1-8
6. Bodey G.P., Buckley M., Sathe Y.S. Quantitative relationships between circulating leukocytes and infection in patients with acute leukemia. Ann Intern Med. 64:(1):1966;328-340
7. Camp-Sorrell D. Chemotherapy: toxicity management. Yarbro C.H., Goodman M., Frogge M.H., Groenwald S.L. Cancer nursing: principles and practice. 5th edition:2000;444-486 Jones and Bartlett, Boston
8. Hughes W.T., Armstrong D., Bodey G.P. 2002 Guidelines for the use of antimicrobial agents in the neutropenic patient with cancer. Clin Infect Dis. 34:2002;730-751
9. Tortorice P.V. Chemotherapy: principles of therapy. Yarbro C.H., Goodman M., Frogge M.H., Groenwald S.L. Cancer nursing: principles and practice. 5th edition:2000;352-385 Jones and Bartlett, Boston
10. MacManus M., Lamborn K., Khan W., et al. Radiotherapy-associated neutropenia and thrombocytopenia: Analysis of risk factor and development of a predictive model. Blood. 89:1997;2303-2310
11. Pickering L.K., Ericsson C.D., Kohl S. Effects of chemotherapeutic agents on metabolic and bactericidal activity of polymorphonuclear leukocytes. Cancer. 42:1978;1741-1746
12. Dean G.E., Haeuber D., Rivera L.M. Infection. McCorkle R., Grant M., Frank-Stromborg M. Cancer nursing: a comprehensive textbook. 2nd edition:1996;963-978 WB Saunders, Philadelphia
13. Zinner S.H. Changing epidemiology of infections in patients with neutropenia and cancer: emphasis on gram-positive and resistant bacteria. Clin Infect Dis. 29:(3):1999;490-494
14. Martin M.A., Pfaller M.A., Wenzel R.P. Coagulase-negative staphylococcal bacteremia. Ann Intern Med. 110:(1):1989;9-16
15. Hospital Infection Control Practices Advisory Committee. Guideline for prevention of intravascular device-related infections. Am J Infect Control [serial online]. 24:1996;262-293. Available from:
16. US Department of Health and Human Services, Centers for Disease Control and Prevention, Atlanta, GA. www.edc.gov/ncidod/hip/iv.htm. Accessed February 20, 2002
17. Edmond M.B., Wallace S.E., McClish D.K., et al. Nosocomial blood stream infections in United States hospitals: a three-year analysis. Clin Infect Dis. 29:(2):1999;239-244
18. Quadri T.L., Brown A.E. Infectious complications in the critically ill patient with cancer. Semin Oncol. 27:(3):2000;335-346
19. Guyton A.C., Hall J.E. Textbook of medical physiology. 10th edition:2000;WB Saunders, Philadelphia
20. Wingard J.R., Chen D.Y.-H., Burns W.H., et al. Cytomegalovirus infection after autologous bone marrow transplantation with comparison to infection after allogeneic bone marrow transplantation. Blood. 71:1988;1432-1437
21. Wingard J.R. Viral infections in leukemia and bone marrow transplant patients. Leuk Lymphoma. 11:1993;115-125
22. Kontoyiannis D.P., Ruoff K., Hooper D.C. Nocardia bacteremia: report of 4 cases and review of the literature. Medicine (Baltimore). 77:1998;255-267
23. Callaghan M.E. Leukemia. McCorkle R., Grant M., Frank-Stromborg M. Cancer nursing: a comprehensive textbook. 2nd edition:1996;752-772 WB Saunders, Philadelphia
24. Ellerhorst-Ryan J.M. Infection. Yarbro C.H., Goodman M., Frogge M.H., Groenwald S.L. Cancer nursing: principles and practice. 5th edition:2000;691-704 Jones and Bartlett, Boston
25. Avery R.K., Longworth D.L. Evolving concepts in the management of patients with neutropenic fever. Cleve Clin J Med. 66:(3):1999;173-180
26. Blot F., Schmidt E., Nitenberg G., et al. Earlier positivity of central venous peripheral blood cultures is highly predictive of catheter-related sepsis. J Clin Microbiol. 35:1998;105-109
27. Wujcki D. Infection. Groenwald S.L., Frogge M.H., Goodman M.L., et al. Cancer symptom management. 1996;289-302 Jones and Bartlett, Boston
28. Linc L.G., Campbell J.M., Kinion E.S. Infections in patients receiving cytotoxic chemotherapy. Medsurg Nursing. 10:(2):2001;61-68
29. Lynch P., Jackson N.M., Cummings J.M., et al. Rethinking the role of isolation practices in the prevention of nosocomial infections. Ann Intern Med. 197:1987;243-245
30. Lynch L.S. Infection in cancer patients. Haskell C.M. Cancer treatment. 4th edition:1995;206-216 WB Saunders, Philadelphia
31. Poe S.S., Larson E., McGuire D., et al. A national survey of infection prevention practices on bone marrow transplant units. Oncol Nurs Forum. 21:1994;1687-1694
32. Shelton B. Sepsis. Semin Oncol Nurs. 15:(3):1999;209-221
33. Howell P.B., Walters P.E., Donowitz G.R., et al. Risk factors for infection of adult patients with cancer who have tunneled central venous catheters. Cancer. 75:1995;1367-1375
34. deMoissac D., Jensen L. Changing IV administration sets: is 48 versus 24 hours safe for neutropenic patients with cancer? Oncol Nurs Forum. 25:(5):1998;907-913
35. Ozer H., Armitage J.O., Bennett C.L., et al. 2000 Update of recommendations for the use of hematopoietic colony-stimulating factors: evidence-based, clinical practice guidelines. J Clin Oncol. 18:2000;3558-3585
36. Zimmer S.H., Klatersky J. Infectious considerations in cancer. Calabrisi P., Schein P.S. Medical oncology. 2nd edition:1993;1073-1100 McGraw-Hill, New York
37. Wilkinson F.H. Bottled water as a source of multi-resistant Stenotrophomonas and Pseudomonas species for neutropenic patients. European Cancer Care. 7:1998;12-14